Copyright
©The Author(s) 2023.
World J Clin Cases. Jun 6, 2023; 11(16): 3736-3749
Published online Jun 6, 2023. doi: 10.12998/wjcc.v11.i16.3736
Published online Jun 6, 2023. doi: 10.12998/wjcc.v11.i16.3736
No. | Drug | Indication |
1 | Topical thymosin β4 | Non-healing epithelial defect |
2 | Topical autologous serum | Promote corneal wound healing |
3 | Topical CT-112 | Reduction in corneal barrier effect |
4 | Topical insulin | Quicker reepithelization after epithelial scraping for vitreoretinal surgeries |
5 | Topical insulin | Prevent sub-basal nerve plexus loss |
6 | Topical insulin | Promote wound healing |
7 | Topical ranirestat | Promote wound healing, control the expression of MMP-10 and integrin α3 expression |
8 | Injection IGF-1 | Prevention of stem cell loss and improve sub-basal nerve plexus density |
9 | Topical naltrexone | Normalize corneal epithelial wound healing, tear film, and corneal sensations |
10 | Nateglinide and glibenclamide | Inhibit descemet membrane changes |
11 | Ciliary neurotrophic factor | Improve epithelial stem cells, increase nerve density and promote epithelial healing |
12 | Topical nerve growth factor | Reduced apoptosis and inflammation |
13 | IL-1 antagonists | Reduced apoptosis, faster wound healing, sensory stimulation, improved Akt signaling |
14 | Substance P | Improved wound healing, reinnervation, and reactivation of EGFR/Akt signaling |
- Citation: Morya AK, Ramesh PV, Kaur K, Gurnani B, Heda A, Bhatia K, Sinha A. Diabetes more than retinopathy, it’s effect on the anterior segment of eye. World J Clin Cases 2023; 11(16): 3736-3749
- URL: https://www.wjgnet.com/2307-8960/full/v11/i16/3736.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i16.3736